FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibit cell growth and induce apoptosis in bladder cancer cells
Toshiya Takamura, Mano Horinaka, Shusuke Yasuda, Seijiro Toriyama, Yuichi Aono, Yoshihiro Sowa, Tsuneharu Miki, Osamu Ukimura and Toshiyuki Sakai
Departments of
1 Molecular-Targeting Cancer Prevention and
2 Urology, Kyoto Prefectural University of Medicine, Kyoto;
3 Department of Urology, Saiseikai Shiga Hospital, Shiga, Japan
Abstract.
In advanced bladder cancer, cisplatin-based chemotherapy has been the standard treatment for many years, but there are many problems in terms of side-effects. Recently, a number of clinical trials using molecular-targeted agents have been conducted, and new therapies are expected that could replace conventional cytotoxic chemotherapy. We herein report that concurrent treatment with fibroblast growth factor receptor (FGFR) inhibitor BGJ398 and the novel histone deacetylase (HDAC) inhibitor OBP-801/YM753/spiruchostatin A synergistically inhibited cell growth and markedly induced apoptosis in high-grade bladder cancer cells. This combination activated caspase-3, -8 and -9, and the pan-caspase inhibitor zVAD-fmk significantly reduced the apoptotic response to the combined treatment. The combination upregulated the expres- sion of Bim, one of the pro-apoptotic molecules. In the present study, Bim siRNA efficiently reduced apoptosis induced by the co-treatment of BGJ398 and OBP-801. Therefore, the apoptosis induced by the combination was shown to be at least partially dependent on Bim. Taken together, these results suggest that the combination of BGJ398 and OBP-801 is a novel high potential therapeutic strategy for muscle-invasive bladder cancer.
Introduction
Bladder cancer is one of the most common cancers in the world, with an estimated 174,000 deaths in 2013 (1). For patients with locally advanced or metastatic bladder cancer, the standard chemotherapy is cisplatin-based combination chemotherapy. However, the 5-year survival rate in patients with stage IV bladder cancer after treatment is only around 15% (2). Considering the limited response rate of the regimens and the toxicity (3), novel therapeutic agents to replace conven- tional cytotoxic chemotherapy are needed.
It has been reported that genetic abnormality of various genes is observed in patients with bladder cancer. Recently, it has become clear that the signaling pathways of fibroblast growth factor receptors (FGFRs), particularly the FGFR3 (4) and FGFR1 (5) pathways, are altered in bladder cancers. FGFRs (FGFR1-FGFR4) play a key role in the regulation of proliferation, angiogenesis and apoptosis (6). The binding of FGFs to FGFRs initiates a phosphorylation cascade, resulting in signaling through various downstream pathways, including RAS-MAPK, PI3K and STATs (7). Active mutations and/or overexpression of FGFR3 are common genetic alterations in non-invasive bladder cancer, but occur at a low frequency in high-grade invasive bladder cancer (8). FGFR1 is not mutated in bladder cancer, but overexpression is frequent in bladder cancer cell lines regardless of tumor grade and stage (5). In addition, it has been reported that FGFR1 expression is an adverse prognostic risk factor in muscle invasive bladder cancer after radical cystectomy (9). Recently, a number of clinical trials of BGJ398, a selective pan FGFR inhibitor, have progressed in patients with various types of cancers. In a phase 1 clinical trial using BGJ398 in patients with solid tumors carrying FGFR genetic alternations, antitumor activity was demonstrated in patients with FGFR3-mutant bladder cancer (10). Furthermore, a study of BGJ398 in non-muscle- invasive urothelial carcinoma of the bladder is currently recruiting participants. FGFR inhibitor BGJ398 is expected to be a more effective therapeutic agent for patients with bladder cancer. However, it has been reported that BGJ398 did not suppress primary tumors, but did inhibit the development of circulating tumor cells and metastasis in vivo (11).
Histone deacetylase (HDAC) inhibitors are also predicted for the treatment of various cancers including bladder cancer. It has been reported that HDAC inhibitors inhibit cell growth and induce cell death in bladder cancer cells (12). Furthermore, several studies have reported that HDAC inhibitors synergize with chemotherapeutic agents (13-15). Currently, a phase 2 clinical trial of an HDAC inhibitor for patients with bladder cancer is ongoing. OBP-801/YM753/spiruchostatin A was identified as a novel HDAC inhibitor by using a p21 promoter- reporter assay, which showed the most potent HDAC-inhibitory activity as compared to other HDAC inhibitors (16).
We showed for the first time that a combined treatment of FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 synergistically inhibited cell growth, and induced apoptosis in human bladder cancer cells. Taken together, we suggest that the combination is a promising novel therapeutic approach to treat muscle-invasive bladder cancer.
Materials and methods
Cell culture.
Human bladder cancer UM-UC-3 and T24 cells were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) and cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml strep- tomycin. Cell cultures were incubated at 37˚C in a humidified atmosphere of 5% CO2.
Reagents.
BGJ398 was purchased from Selleck Chemicals (Houston, TX, USA). OBP-801 was supplied by Oncolys BioPharma (Tokyo, Japan). zVAD-fmk was purchased from R&D Systems (Minneapolis, MN, USA). BGJ398, OBP-801 and zVAD-fmk were dissolved in dimethyl sulfoxide (DMSO).
Cell viability assay.
The number of viable cells was deter- mined using the Cell Counting Kit-8 (CCK-8) assay according to the manufacturer’s instructions (Dojindo Laboratories, Kumamoto, Japan). After the incubation of cells (3×103/well) in 96-well plates for 72 h with the indicated concentrations of BGJ398 or OBP-801, the kit reagent was added to the medium, and the plates were incubated for a further 4 h. The absorbance of samples (450 nm) was determined using a scanning multi- well spectrophotometer (DS Pharma Biomedical, Co., Ltd., Osaka, Japan).
Combination index.
Combination index (CI) values were analyzed using CalcuSyn software (Biosoft, Great Shelford, UK). CI <1 indicates synergism greater than the expected additive effect.
Detection of apoptosis.
After the incubation of cells (2×104/ well) in 6-well plates for 72 h with the agents, the cells were harvested. After washing with phosphate-buffered saline (PBS), the cells were treated with PBS containing 0.1% Triton X-100 and the nuclei were stained with propidium iodide (PI; Sigma-Aldrich, St. Louis, MO, USA). The DNA content was measured using a FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA). CellQuest software (Becton-Dickinson) was used to analyze the data. DNA fragmentation was quantified by the percentage of hypodiploid DNA (sub-G1).
Western blotting.
Western blot analysis was carried out as previ- ously described (17). The following antibodies were purchased from the indicated sources: rabbit monoclonal antibodies for anti-Bim (ab32158) (Abcam, Cambridge, UK), anti-Bcl-xL (#2762), and anti-PARP (#9542) (Cell Signaling Technology, Beverly, MA, USA); rabbit polyclonal antibodies for anti- survivin (AF886) (R&D Systems), anti-DR5 (#8074) (Cell Signaling Technology), anti-DR4 (1139) (ProSci, Inc., Poway, CA, USA), anti-caspase-3 (#9665), anti-histone H4 (#2935), anti-acetyl-histone H4 (#9672), anti-Bid (#2002), anti-ERK1/2 (#9102), anti-Shp2 (#3752), anti-phospho ERK1/2 (#9101), anti-phospho FRS2-α (#3861), anti-phospho Shp2 (#3751) (Cell Signaling Technology), anti-FRS2-α (SC17841) (Santa Cruz Biotechnology, Dallas, TX, USA); mouse monoclonal anti- bodies for anti-caspase-8 (M032-3) and anti-caspase-9 (M054-3) (MBL, Nagoya, Japan), anti-FLIP (ACX-804-961-0100) (Enzo Life Sciences, Farmingdale, NY, USA), and anti-GAPDH (5G4) (HyTest, Ltd., Turku, Finland) were used as primary antibodies. An anti-rabbit IgG-HRP-conjugated antibody (NA934) (GE Healthcare Life Sciences, Little Chalfont, UK) and an anti- mouse IgG-HRP-conjugated antibody (NA931) (GE Healthcare Life Sciences) were used as the secondary antibodies. The signal was detected using the Chemilumi-One chemiluminescent kit (Nacalai Tesque, Inc., Kyoto, Japan) or chemiluminescent HRP substrate (Millipore, Billerica, MA, USA).
Small interfering RNA transfection.
The Bim siRNA and the negative control siRNA were purchased from Sigma-Aldrich. The Bim siRNA (ACUUACAUCAGAAGGUUGC) was used for the transfection. At the same time as the transfection, UM-UC-3 and T24 cells (2×104/well) were seeded in 6-well plates without antibiotics. The Bim siRNA (5 nM for UM-UC-3 cells or 10 nM for T24 cells) was transfected into cells using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s instructions. Twenty-four hours after the transfection, the cells were treated with agents for 48 h and then harvested.
Statistical analysis.
Data are expressed as the means ± SD of three determinations. Statistical analysis was performed using a Student’s t-test. Samples were considered significantly different at P<0.05.
Results
Combined treatment with BGJ398 and OBP-801 synergisti- cally inhibits cell growth in human bladder cancer cells. To examine the anti-growth effects of BGJ398 or OBP-801 alone against human bladder cancer cells, we first assessed the viable cell number at 72 h after treatment with the indicated concen- trations of the agents. Each agent suppressed the cell growth of UM-UC-3 and T24 cells in a dose-dependent manner (Fig. 1A). Notably, co-treatment with BGJ398 and OBP-801 markedly inhibited cell growth, compared with the single treatment of each agent in both cell lines (Fig. 1B). Moreover, the combination index (CI) values for BGJ398 and OBP-801 were <1.0, indicating a synergistic effect on the inhibition of cell growth (Table I).
We next examined the effects of the combined treatment of FGFR inhibitor BGJ398 and HDAC inhibitor OBP-801 the phosphorylation of FGFR substrate 2 (FRS2), which is a docking protein linking FGFRs, in UM-UC-3 cells. Furthermore, BGJ398 also inhibited the phosphorylation of ERK in UM-UC-3 cells (Fig. 2B). On the other hand, BGJ398 slightly inhibited phosphorylation of FRS2, and the co-treatment of OBP-801 and BGJ398 more clearly inhibited it in T24 cells. However, the treatment of BGJ398 alone and the combination did not inhibit the phosphorylation of ERK in T24 cells (Fig. 2B). Therefore, we next examined the effect of the combination on the phosphorylation of protein tyrosine phosphatase Shp2. Shp2 is a critical downstream mediator of FGFR-FRS2 signaling. As shown in Fig. 2B, the combined treatment inhibited the phosphorylation of Shp2 in T24 cells.
The co-treatment with BGJ398 and OBP-801 more markedly induced apoptosis than that of each agent alone in the UM-UC-3 and T24 cells (Fig. 3). To examine whether the apoptosis induced by the combination of the agents is caspase-dependent, we analyzed the effect of a caspase inhibitor. The pan-caspase inhibitor zVAD-fmk effectively blocked apoptosis induced by the co-treatment with BGJ398 and OBP-801 (Fig. 3). These results suggest that the combination of BGJ398 and OBP-801 synergistically induces caspase-dependent apoptosis in human bladder cancer cells.
Combined treatment with BGJ398 and OBP-801 causes apop- tosis via intrinsic and extrinsic pathways in human bladder cancer cells. We examined the expression of apoptosis-related proteins in the combined treatment. As shown in Fig. 4, the concurrent treatment induced the cleavage of caspase-8, caspase-9, caspase-3 and PARP. The co-treatment increased the expression of pro-apoptotic protein Bim, and reduced the expression of anti-apoptotic proteins, survivin and FLIPL, in UM-UC-3 and T24 cells (Fig. 4). The expression of DR5, one of the pro-apoptotic proteins, was upregulated by co-treatment in UM-UC-3 cells, but not in T24 cells. These results suggest that the combined treatment with BGJ398 and OBP-801 induced apoptosis through the activation of both intrinsic and extrinsic pathways in human bladder cancer cells.
Bim contributes to apoptosis by the combined treatment in bladder cancer cells. The combined treatment upregulated the expression of Bim in the UM-UC-3 and T24 cells (Fig. 4). We examined whether Bim contributed to the induction of apoptosis by co-treatment with BGJ398 and OBP-801. The effects of the Bim knockdown were confirmed by western blotting (Fig. 5). Bim siRNA significantly suppressed apop- tosis induced by the combination compared with the control (Fig. 5). These results suggest that the combined treatment with BGJ398 and OBP-801 caused apoptosis at least partially through the upregulation of Bim in bladder cancer cells.
Discussion
In the present study, we showed for the first time the syner- gistic effect of the combined treatment with FGFR inhibitor BGJ398 and the novel HDAC inhibitor OBP-801 on cell growth arrest and apoptosis against high grade bladder cancer cells. Furthermore, the apoptosis was associated with the upregulation of Bim and DR5, and downregulation of survivin and FLIP by the combined treatment as the molecular mecha- nisms. In these apoptosis-related proteins, we showed that Bim knockdown significantly inhibited apoptosis induced by the combination (Fig. 5). The results suggest that the combined treatment causes apoptosis at least partially through the upregulation of Bim in bladder cancer cells.
Bim is a BH3-only pro-apoptotic member of the Bcl-2 family (18), and its expression is regulated by ERK1/2 and PI3K/ AKT pathways (19). The activation of the ERK1/2 pathway induces the phosphorylation of Bim and promotes proteasome- dependent degradation of phosphorylated Bim (20). In the present study, OBP-801 slightly inhibited the phosphorylation of ERK1/2 in UM-UC-3 cells (Fig. 2B). A previous report showed that HDAC inhibitors decreased phosphorylation of ERK by upregulating dual-specificity phosphatase (DUSP) (21). DUSP may be involved in the downregulation of ERK1/2 by OBP-801 in UM-UC-3 cells. On the other hand, the effect of BGJ398 was different in the UM-UC-3 and in T24 cells. BGJ398 clearly inhibited the phosphorylation of ERK1/2 in UM-UC-3 cells (Fig. 2B). The phosphorylation of ERK1/2 was more clearly inhibited by the co-treatment of BGJ398 and OBP-801 in UM-UC-3 cells (Fig. 2B). These results suggest that the expression of Bim was upregulated by the combination in ERK1/2-dependent pathways in UM-UC-3 cells.
In the present study, BGJ398 alone and co-treatment with OBP-801 inhibited the phosphorylation of FRS2 in T24 cells (Fig. 2B). On the other hand, the phosphorylation of ERK was not suppressed by these treatments in T24 cells (Fig. 2B). Therefore, we next examined whether the combination regu- lated Shp2 downstream of FGFR-FRS2 signaling independent of ERK. Shp2, a non-receptor phosphotyrosine phosphatase, promotes tumor progression in various cancer types (22). Furthermore, previous studies reported that Shp2 is a key downregulator of Bim through ERK1/2 activation (23,24). Notably, in this study, the combination inhibited phosphory- lation of Shp2 but not the phosphorylation of ERK in T24 cells. These data showed that Bim was upregulated by Shp2 independent of ERK in T24 cells treated by the combination, suggesting the existence of an unknown pathway between Shp2 and Bim independent of ERK.
Moreover, the expression of DR5 was upregulated by the combination in UM-UC-3 cells (Fig. 4). We previously reported that OBP-801 and celecoxib synergistically induced apoptosis via the DR5-dependent pathway, and that Bim partially acts as one of the key molecules downstream of DR5 in bladder cancer cells (17). Therefore, the DR5-dependent pathway may be partially involved in the caspase-dependent apoptosis by the combination of BGJ398 and OBP-801 in UM-UC-3 cells.
In conclusion, this is the first report showing the synergistic effect of the combination of an FGFR inhibitor and an HDAC inhibitor against human bladder cancer cells. We suggest that the combined treatment is a promising novel therapeutic approach to treat muscle-invasive bladder cancer.